Jakarta, April 13th, 2022. PT Kalbe Farma Tbk (Kalbe), in collaboration with PT Metiska Farma, improves access to medicine for the society by promoting Antiten-A, a blood thinner medication or an anticoagulant that contains enoxaparin. This medication can limit the activity of protein for blood-clotting, preventing the formation of a blood clot.

Jakarta, April 7th, 2022. PT Kalbe Farma Tbk (Kalbe) is ready to commit in establishing the sustainability initiative, which includes the gender equality. In its establishment, Kalbe presents the TAS (Talk About Sustainability) program, aimed to build the sustainability culture in the Kalbe Group.

Jakarta, April 2nd, 2022. PT Kalbe Farma Tbk (Kalbe), through Kalbe Ethical Customer Care (KECC), declares kidney health for all in commemorating the World Kidney Day of 2022. This event is a collaboration of Kalbe with the Indonesia Kidney Care Club (IKCC) and the Siloam Hospital of Simatupang.

Jakarta, March 31, 2022 – PT Kalbe Farma Tbk and Subsidiaries (“Kalbe” or “the Company”) today announced that net sales reached Rp 26,261 billion in 2021, growing by 13.6% compared to 2020. Meanwhile, net income of the owners of the parent entity reached Rp 3,184 billion in 2021, grew by 16.5% compared to Rp 2,733 billion in 2020.